Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study

The treatment of acquired hemophilia (AH) involves discussing whether corticosteroids should be administered alone or combined with immunosuppressant drugs, which increase the risk of infection especially in elderly patients and/or those with autoimmunity or neoplastic diseases, who represent the ta...

Full description

Bibliographic Details
Main Authors:	Vautier, Mathieu, de Boysson, Hubert, Creveuil, Christian, Repesse, Yohan, Borel-Derlon, Annie, Troussard, Xavier, Damaj, Gandhi L., Bienvenu, Boris, Gautier, Philippe, Aouba, Achille
Format:	Online
Language:	English
Published:	Wolters Kluwer Health 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134779/

Similar Items

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
by: Saba, Hussain I, et al.
Published: (2011)

Efficacy of Corticosteroids Alone in the Eradication of Factor VIII Inhibitor in an Old Female with Idiopathic Acquired Haemophilia A: Description of a Case
by: Girelli, Francesco, et al.
Published: (2012)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
by: Oh, Jisu, et al.
Published: (2013)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
by: Karakuş, Volkan, et al.
Published: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
by: Abt, Nicholas B., et al.
Published: (2014)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
by: Wynn, Tung Thanh, et al.
Published: (2016)

Neutrophilic Dermatoses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A French Multicenter Study of 17 Cases and Literature Review
by: de Boysson, Hubert, et al.
Published: (2016)

Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern
by: de Boysson, Hubert, et al.
Published: (2016)

Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
by: Tjønnfjord, Geir E, et al.
Published: (2007)

Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study
by: Halimeh, Susan, et al.
Published: (2013)

Endoscopic Diagnosis of Intramural Hematoma in The Colon sigmoideum In a Child With High Titer Inhibitory Hemophilia A
by: Yankov Ivan V., et al.
Published: (2014-08-01)

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A
by: Roth, Stefanie D., et al.
Published: (2012)

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A
by: Johnston, Jennifer M., et al.
Published: (2012)

A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A
by: Tatsumi, Kohei, et al.
Published: (2013)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
by: Doshi, Bhavya S., et al.
Published: (2012)

The Association Between HLA Class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A
by: Nathalang, Oytip, et al.
Published: (2012)

Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
by: Bhavya S Doshi, et al.

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
by: Chowdary, Pratima, et al.
Published: (2016)

Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice
by: Lange, Amy M, et al.
Published: (2016)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
by: Miao, Carol H.
Published: (2016)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
by: Krishnamoorthy, Sriram, et al.
Published: (2015)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
by: Castaman, Giancarlo, et al.
Published: (2016)

Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment
by: Wang, Qizhao, et al.
Published: (2016)

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center
by: Yoo, Ki Young, et al.
Published: (2016)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
by: Valizadeh, Leila, et al.
Published: (2015)

Complete Remission of Generalized Myasthenia Gravis by Corticosteroid Treatment Alone without Thymectomy
by: Kataoka, Hiroshi, et al.
Published: (2011)

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
by: Rasekh, Hamid Reza, et al.
Published: (2011)

Acquired Hemophilia
by: Özsoylu, Şinasi
Published: (2014)

Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature
by: Aouba, A., et al.
Published: (2015)

18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients
by: de Boysson, Hubert, et al.
Published: (2016)

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A
by: Pandey, G., et al.
Published: (2013)

A novel mutation (4040-4045 nt. delA) in exon 14 of the factor VIII gene causing severe hemophilia A
by: Onsori, Habib, et al.
Published: (2011)

Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice
by: Liu, Chao Lien, et al.
Published: (2014)

Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review
by: Nigel P. Murray, et al.
Published: (2018-01-01)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
by: Coyle, T E, et al.
Published: (2014)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
by: Brown, Harrison C, et al.
Published: (2014)

Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia A
by: Matsui, Hideto, et al.
Published: (2014)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
by: Pocoski, Jennifer, et al.
Published: (2016)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
by: Sudheesh, K. M., et al.
Published: (2016)

Prevention of the Musculoskeletal Complications of Hemophilia
by: Rodriguez-Merchan, E. C.
Published: (2012)